Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.

Molecular cancer therapeutics - 1 Apr 2017

Salgia Ravi

Abstract excerpt

MET or hepatocyte growth factor (HGF) receptor pathway signaling mediates wound healing and hepatic regeneration, with pivotal roles in embryonic, neuronal, and muscle development. However, dysregulation of MET signaling mediates proliferation, apoptosis, and migration and is implicated in a number of malignancies. In non-small cell lung cancer (NSCLC), aberrant MET signaling can occur through a number of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Amplification

Share to Hepatocyte Growth Factor

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 28373408
DOI: 10.1158/1535-7163.MCT-16-0472

Genes

MET
HGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.PMID 28373408Read ↗

Prognostic and predictive value of MET deregulation in non-small cell lung cancer.Semantic proximity Read ↗

The METeoric rise of MET in lung cancerSemantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

MET as a possible target for non-small-cell lung cancer.Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

Overview of Molecular Detection Technologies for MET in Lung CancerSemantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Met inhibitors in the treatment of lung cancer: the evidence to date.Semantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alterationSemantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

Biomarker development in MET-targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.